

Appendice X. Fattori di rischio per le Infezioni nelle donne in gravidanza.

Fattori di rischio	Consumo di carni crude o poco cotte (inclusi affettati, carne secca, etc.) o di frutta a verdura mal lavata														
	Consumo di carne poco cotta di animali selvatici o di succo di canna da zucchero														
	Altro														
	Provenienza da / soggiorno > 6 mesi in / permanenza in aree rurali in / avere la madre proveniente da Paesi endemici per malattia di Chagas ^a														
	Lavande vaginali														
	Utilizzo di strumenti non sterili in trattamenti estetici, piercing, tatuaggi, altre esposizioni percutanee														
	Contatto con feci di gatto o di altro materiale contaminato (terra, acqua)														
	Contatto con bambini di età < 3 anni														

^a PrEP: profilassi pre-esposizione per la prevenzione di HIV

^b MSM: maschi che hanno rapporti sessuali con maschi

^c soprattutto se sieropositivi per HIV o se assumono PrEP

^d FSF: femmine che hanno rapporti sessuali con femmine

^e Argentina, Belize, Bolivia, Brasile, Cile, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Guyana, Guyana francese, Honduras, Messico, Nicaragua, Panama, Paraguay, Perù, Suriname, Uruguay, Venezuela (escluse le isole caraibiche)

Bibliografia:

1. Workowski, K. A., Bachmann, L. H., Chan, P. A., et al. (2021). Sexually Transmitted Infections Treatment Guidelines, 2021. *MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports*, 70(4), 1–187.
2. Wingert, A., Pillay, J., Sebastianski, M., et al. (2019). Asymptomatic bacteriuria in pregnancy: systematic reviews of screening and treatment effectiveness and patient preferences. *BMJ open*, 9(3), e021347.
3. Nicolle, L. E., Gupta, K., Bradley, S. F., et al. (2019). Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. *Clinical infections diseases : an official publication of the Infectious Diseases Society of America*, 68(10), e83–e110.
4. Salfa, M.C., Ferri, M., Suligoi, B., et al. (2022). Le infezioni sessualmente trasmesse: aggiornamento dei dati dei due sistemi di sorveglianza sentinella attivi in Italia al 31 dicembre 2020. *Not Ist Super Sanità*, 35(6):3-39
5. Cantor, A., Dana, T., Griffin, J.C., et al. (2021). *Screening for Chlamydial and Gonococcal Infections: A Systematic Review Update for the U.S. Preventive Services Task Force*. Agency for Healthcare Research and Quality (US).
6. European Centre for Disease Prevention and Control. Syphilis. Annual epidemiological report for 2019. (2022). Testo integrale: <https://www.ecdc.europa.eu/en/publications-data/syphilis-annual-epidemiological-report-2019>. (data di accesso: 20/09/2023)
7. European Centre for Disease Prevention and Control. Syphilis and congenital syphilis in Europe – A review of epidemiological trends (2007–2018) and options for response.(2019). Testo integrale: <https://www.ecdc.europa.eu/en/publications-data/syphilis-and-congenital-syphilis-europe-review-epidemiological-trends-2007-2018>. (data di accesso: 20/09/2023)

8. National Health Service (NHS). Health A to Z. Syphilis. (2022). Testo integrale: <https://www.nhs.uk/conditions/syphilis/> (data di accesso: 20/09/2023)
9. Istituto Superiore di Sanità. EpiCentro – L'epidemiologia per la sanità pubblica. Epatite virale - Epidemiologia - dati SEIEVA. (2022). Testo integrale: <https://www.epicentro.iss.it/epatite/dati-seieva#b> (ultimo accesso il 10/10/2023).
10. Schillie, S., Vellozzi, C., Reingold, A., et al. (2018). Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. *MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports*, 67(1), 1–31.
11. Centers for Disease Control and Prevention (2001). Revised guidelines for HIV counseling, testing, and referral. *MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports*, 50(RR-19), 1–19a1.
12. Chou, R., Huffman, L. H., Fu, R., et al., US Preventive Services Task Force (2005). Screening for HIV: a review of the evidence for the U.S. Preventive Services Task Force. *Annals of internal medicine*, 143(1), 55–73.
13. Selph, S. S., Bougatsos, C., Dana, T., Grusing, S., & Chou, R. (2019). *Screening for HIV Infection in Pregnant Women: A Systematic Review for the U.S. Preventive Services Task Force*. Agency for Healthcare Research and Quality (US).
14. Wald A. (2006). Genital HSV-1 infections. *Sexually transmitted infections*, 82(3), 189–190.
15. *Updated Recommendations on Treatment of Adolescents and Children with Chronic HCV Infection, and HCV Simplified Service Delivery and Diagnostics*. (2022). World Health Organization.
16. American College of Obstetricians and Gynecologists. (2020). *Prevention of Group B Streptococcal Early-Onset Disease in Newborns: ACOG Committee Opinion, Number 797*. *Obstet Gynecol* Feb;135(2): e51-e72.
17. Adler, S. P., & Marshall, B. (2007). Cytomegalovirus infections. *Pediatrics in review*, 28(3), 92–100.
18. Murph, J. R., Baron, J. C., Brown, C. K., et al. (1991). The occupational risk of cytomegalovirus infection among day-care providers. *JAMA*, 265(5), 603–608.
19. Contopoulos-Ioannidis D, Montoya JG. (2013) *T. gondii and toxoplasmosis*. In: Long S, Pickering L, Prober C, eds. *Principles and Practice of Pediatric Infectious Diseases*, 4th ed. Saunders.
20. Cook, A. J., Gilbert, R. E., Buffolano, W., et al. (2000). Sources of toxoplasma infection in pregnant women: European multicentre case-control study. European Research Network on Congenital Toxoplasmosis. *BMJ (Clinical research ed.)*, 321(7254), 142–147.
21. Paquet, C., & Yudin, M. H. (2018). No. 285-Toxoplasmosis in Pregnancy: Prevention, Screening, and Treatment. *Journal of obstetrics and gynaecology Canada: JOGC = Journal d'obstétrique et gynécologie du Canada : JOGC*, 40(8), e687–e693.
22. Associazione Microbiologi Clinici Italiani (AMCLI), (2023) Percorso diagnostico Infezioni a trasmissione verticale virus della rosolia. URL: <https://www.amcli.it/documenti/percorsi-diagnostici/> (accesso 12/07/2023).
23. Jonas, D. E., Riley, S., Lee, L.,(2023). Screening for Latent Tuberculosis Infection in Adults: An Evidence Review for the U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality (US).
24. WHO (World Health Organization) consolidated guidelines on tuberculosis. Module 2: screening – systematic screening for tuberculosis disease. Geneva: World Health Organization; 2021a Testo integrale: <https://apps.who.int/iris/handle/10665/340255> (Ultimo accesso il 12/07/2023).
25. Comitato di Studio per la Parassitologia dell'Associazione Microbiologi Clinici Italiani (AMCLI-CoSP). Percorso diagnostico delle parassitosi ematiche e del sistema reticollo endoteliale (SRE). 2020. Testo integrale: http://www.amcli.it/wp-content/uploads/2020/06/PARASSITOSI-EMATICHE-PERCORSO-DIAGNOSTICO-DEFINITIVO-12_06_2020.pdf (ultimo accesso il 19/09/2023).
26. Forsyth, C. J., Manne-Goehler, J., Bern, C., Whitman, J., et al. (2022). Recommendations for Screening and Diagnosis of Chagas Disease in the United States. *The Journal of infectious diseases*, 225(9), 1601–1610.
27. Velasco M, Gimeno-Feliu LA, Molina I, Salas-Coronas J, et al. (2020). Screening for *Trypanosoma cruzi* infection in immigrants and refugees: Systematic review and recommendations from the Spanish Society of Infectious Diseases and Clinical Microbiology. *Euro surveillance : bulletin European sur les maladies transmissibles = European communicable disease bulletin*, 25(8), 1900393.